{'fraction_non_alphanumeric': 0.04076086956521739, 'fraction_numerical': 0.020380434782608696, 'mean_word_length': 5.353448275862069, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In vitro response to mitogens and antigens in elderly and post-cytotoxic patients can be modified by a new hypoxanthine derivative (PCF-39).

The in vitro immunomodulatory properties of the hypoxanthine derivative N alpha-5(1.6-dihidro-6-oxo-9-purinyl)pentyloxy/carbonyl -L-arginine (PCF-39) are described. Data obtained with PHA in vitro indicate that PCF-39 exhibits immunopharmacologic activity in elderly and post-cytotoxic patients, while showing no significant activity in normal donors. Antigen induced proliferation was unaffected by PCF-39, while PMN induced chemiluminescence was significantly enhanced. PCF-39 can be considered a new drug in the family of the hypoxanthine derivatives endowed with immunomdulatory properties.